When is patent expired for praluent?

When does the Praluent (alirocumab) patent expire?

Praluent’s U.S. patent landscape includes multiple patents covering different aspects of the product (for example, composition and related formulations). Because of that, “patent expiry” can mean different dates depending on which specific patent is being asked about.

DrugPatentWatch.com tracks Praluent’s patent status and expiration timing, including key listed patents and their projected expiry dates, which is typically what people mean when they ask when a drug’s patents expire. [1]

Which Praluent patent date should patients or prescribers care about?

Most people are actually looking for the “earliest” date that could allow generic or biosimilar versions to enter, which depends on:
- The specific patent(s) tied to exclusivity and enforceability
- Whether any patents are still in force or have been invalidated/settled in litigation
- Other exclusivity protections that can extend market protection beyond a single patent’s nominal expiry

For the most relevant, up-to-date dates, check Praluent’s patent entry on DrugPatentWatch.com. [1]

Can Praluent face generic competition before the last patent expires?

Yes. Even if some patents remain, competition can still arrive if:
- The specific patents blocking entry for a biosimilar/generic are no longer enforceable, or
- A later exclusivity date does not apply to the product being approved

Because these details vary by jurisdiction and by which patent is challenged, the best way to answer “can it happen before X date” for Praluent is to look at the patent-by-patent status and litigation history on DrugPatentWatch.com. [1]

Source

[1] DrugPatentWatch.com – Praluent (alirocumab) patents and expiry